COMMUNIQUÉS West-GlobeNewswire

MDxHealth lance AssureMDx, un test de biopsie liquide pour la détection du cancer de la vessie
06/07/2017
Une étude révèle que le test pourrait réduire les techniques invasives de diagnostic de 77 % COMMUNIQUE DE PRESSE / INFORMATION REGLEMENTAIRE / INFORMATION PRIVILEGIEE IRVINE, CA, and HERSTAL, BELGIQUE - 07:00 CEST, 6 [...]
Le candidat-médicament QRX-411 de ProQR pour le syndrome d'Usher obtient la désignation d'Orphan Drug (médicament orphelin) de la FDA et de l'EMA
06/07/2017
Principaux résultats Le QRX-411 de ProQR obtient la désignation Orphan Drug (médicament orphelin) par la FDA et l'EMA pour le traitement de la rétinite pigmentaire, y compris le syndrome d'Usher, le sous-type ciblé par [...]
Taconic Biosciences and Pharmatest Services Ltd. Create First Human Immune System Model for Bone Metastasis
05/07/2017
Researchers hopeful this new model will address incurable and painful disease HUDSON, N.Y., July 05, 2017 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in genetically engineered mouse models and associated [...]
ETC's Sterilization Systems Group Awarded Eight Contracts
05/07/2017
For Immediate Release SOUTHAMPTON, PA, USA , July 5, 2017 - Environmental Tectonics Corporation's (OTC Pink: ETCC) ("ETC" or the "Company") Sterilization Systems Group ("SSG") today announced that calendar year to date [...]
Bilan semestriel du contrat de liquidité DBV Technologies contractés avec Natixis
05/07/2017
Informations Réglementées Montrouge, France, le 05 juillet 2017, 22h30 CEST Bilan semestriel du contrat de liquidité DBV Technologies contractés avec Natixis Montrouge, France le 5 juillet 2017 - Au titre du contrat de [...]
Half-Year Report on the DBV Technologies Liquidity Contract with Natixis
05/07/2017
AMF REGULATED INFORMATION Montrouge, France, July 5, 2017 Half-Year Report on the DBV Technologies Liquidity Contract with Natixis Under the liquidity contract between DBV TECHNOLOGIES and NATIXIS, the following assets [...]
Minerva Neurosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
05/07/2017
WALTHAM, Mass., July 05, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced public offering of 5,750, [...]
Prothena Announces Initiation of Phase 2 PASADENA Study of PRX002/RG7935 in Patients with Early Parkinson's Disease
05/07/2017
First potentially disease-modifying anti-alpha-synuclein antibody to be evaluated for efficacy in patients with Parkinson's disease Prothena to receive $30 million milestone payment under collaboration agreement with [...]
Arques Clinic : FAB Generation: Fabulous at Fifty and Beyond
05/07/2017
MARBELLA, SPAIN--(Marketwired - Jul 5, 2017) - Being 50 years old has really changed in the last 20 years and now doesn't feel that old. The classic stereotype is being replaced by a new standard: the Fabulous at Fifty [...]
Nature Publication Reports Favorable Clinical Trial Results of BioNTech's Individualized Cancer Vaccine IVAC® MUTANOME
05/07/2017
- First-ever clinical study demonstrates personalized RNA-based vaccine using mutant neo-epitopes as antigens activates immune system against individual mutations and exerts anti-cancer activity - MAINZ, Germany, July [...]
Essilor : Nombre total de droits de vote et d'actions composant le capital social au 30 juin 2017
05/07/2017
Nombre total de droits de vote et d'actions composant le capital social au 30 juin 2017 (Article L.233-8 II du Code de Commerce et les articles 221-1 et 223-16 du Règlement Général de l'AMF) Charenton-le-Pont, France ( [...]
Essilor: Disclosure of Share Capital and Voting Rights Outstanding as of June 30, 2017
05/07/2017
Disclosure of Share Capital and Voting Rights Outstanding as of June 30, 2017 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]
Deinove : le processus d'industrialisation du programme caroténoïdes entre en phase II
05/07/2017
DEINOVE : LE PROCESSUS D'INDUSTRIALISATION DU PROGRAMME CAROTÉNOÏDES ENTRE EN PHASE II La Phase I du programme a permis de sélectionner la première molécule caroténoïde qui sera produite à échelle industrielle courant [...]
Deinove: the industrialization process of the carotenoids program enters phase II
05/07/2017
DEINOVE: THE INDUSTRIALIZATION PROCESS OF THE CAROTENOIDS PROGRAM ENTERS PHASE II Phase I of the program selected the first carotenoid molecule to be produced on an industrial scale in 2018. The yields obtained in 20- [...]
Solon Eiendom ASA - Primary insider notification
05/07/2017
SOLON EIENDOM ASA STOCK EXCHANGE ANNOUNCEMENT Solon Eiendom ASA - Primary insider notification (Oslo, Norway, 5 July 2017) Solon Eiendom ASA Board Member Tore Aksel Voldberg (through his wholly owned company Skøien AS) [...]
ProMIS Neurosciences to Present Preclinical Data from Alzheimer's Disease Program at AAIC 2017
05/07/2017
Chief Development Officer Dr. Johanne Kaplan to chair session ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC): 16-20 JULY, 2017 LONDON, ENGLAND TORONTO, Ontario and CAMBRIDGE, Massachusetts - July 5, 2017 - [...]
Medibio Appoints Mental Healthcare Advocate and Former Congressman, Patrick Kennedy, to Board of Directors
05/07/2017
SYDNEY, Australia and MINNEAPOLIS, July 05, 2017 (GLOBE NEWSWIRE) -- Australian Stock Exchange listed medical technology company Medibio Limited (MEB or the Company) is pleased to announce the appointment of The [...]
Auris Medical Completes Enrollment of Phase 3 HEALOS Trial of AM-111 for the Treatment of Sudden Deafness
05/07/2017
Top-line results from the HEALOS trial are expected in the fall of 2017 Zug, Switzerland, July 5, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that [...]
ProQR's Drug Candidate QRX-411 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA
05/07/2017
Key Updates ProQR's QRX-411 receives Orphan Drug Designation by the FDA and EMA for the treatment of retinitis pigmentosa, including Usher syndrome, the subtype targeted by QRX-411. Usher syndrome is an inherited [...]

Pages